| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1915 | 2016 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 1153 | 2022 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 926 | 2020 |
| Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates AO Hoff, BB Toth, K Altundag, MM Johnson, CL Warneke, M Hu, A Nooka, ... Journal of Bone and Mineral Research 23 (6), 826-836, 2008 | 871 | 2008 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 741 | 2019 |
| Ide-cel or standard regimens in relapsed and refractory multiple myeloma P Rodriguez-Otero, S Ailawadhi, B Arnulf, K Patel, M Cavo, AK Nooka, ... New England Journal of Medicine 388 (11), 1002-1014, 2023 | 704 | 2023 |
| Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ... Nature communications 9 (1), 5341, 2018 | 575 | 2018 |
| Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results AM Lesokhin, MH Tomasson, B Arnulf, NJ Bahlis, H Miles Prince, ... Nature medicine 29 (9), 2259-2267, 2023 | 554 | 2023 |
| Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ... Haematologica 98 (11), 1753, 2013 | 413 | 2013 |
| Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, ... The lancet oncology 15 (3), 333-342, 2014 | 365 | 2014 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 332 | 2018 |
| Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case–control study YH Shaib, HB El-Serag, AK Nooka, M Thomas, TD Brown, YZ Patt, ... Official journal of the American College of Gastroenterology| ACG 102 (5 …, 2007 | 323 | 2007 |
| Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma YZ Patt, MM Hassan, A Aguayo, AK Nooka, RD Lozano, SA Curley, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 297 | 2004 |
| Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, ... Journal of Clinical Oncology 38 (17), 1928-1937, 2020 | 279 | 2020 |
| Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients AK Nooka, JL Kaufman, S Muppidi, A Langston, LT Heffner, C Gleason, ... Leukemia 28 (3), 690-693, 2014 | 236 | 2014 |
| Treatment options for relapsed and refractory multiple myeloma AK Nooka, E Kastritis, MA Dimopoulos, S Lonial Blood, The Journal of the American Society of Hematology 125 (20), 3085-3099, 2015 | 234 | 2015 |
| American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and … S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, ... Biology of Blood and Marrow Transplantation 21 (12), 2039-2051, 2015 | 225 | 2015 |
| Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR MV Mateos, P Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 509-518, 2020 | 208 | 2020 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a … SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ... The Lancet Oncology 23 (1), 65-76, 2022 | 201 | 2022 |
| Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, ... Blood Cancer Journal 9 (12), 94, 2019 | 201 | 2019 |
